Dr Tan See Leng ("Dr Tan") shall cease as the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") at the expiry of his contract of employment on 31 December 2019.

Dr Tan was appointed the Managing Director and Chief Executive Officer ("CEO") of IHH in January 2014 after serving as an Executive Director on the IHH Board for 2 years. Dr Tan is currently the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and on a Board Committee of ASYH. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust, which is listed on the Singapore Exchange Securities Trading Limited.

Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to a leading global health-plan and insurance provider.

With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees, such as Singapore Ministry of Health's MediShield Life Review Committee. He has been reappointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education, for the period until 2019.

Nil

Nil

Dr Tan's interest as at 27 May 2019 is as follows: 

Direct interest in IHH: 
1) 2,863,300 ordinary shares 
2) 1,308,000 Long Term Incentive Plan units 
3) 20,661,000 Enterprise Option Scheme options

Direct interest in a subsidiary:
Parkway Pantai Limited [USD500 million 4.25% Senior Perpetual Securities] - Value of securities held: USD3,000,000